Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Read at The Sydney Morning Herald(opens in a new tab)
Full coverage
Amplia gets nod for new cancer drug trial ahead of US push (opens The Age in a new tab)
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Amplia gets nod for new cancer drug trial ahead of US push (opens The Sydney Morning Herald in a new tab)
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
